{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T17:17:26Z","timestamp":1787678246492,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.prp.2017.08.003","type":"journal-article","created":{"date-parts":[[2017,8,25]],"date-time":"2017-08-25T22:45:32Z","timestamp":1503701132000},"page":"1282-1288","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["p38MAPK family isoform p38\u03b1 and activating transcription factor 2 are associated with the malignant phenotypes and poor prognosis of patients with ovarian adenocarcinoma"],"prefix":"10.1016","volume":"213","author":[{"given":"Wan-Juan","family":"Song","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan-Yuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2017.08.003_bib0005","doi-asserted-by":"crossref","first-page":"e13770","DOI":"10.1371\/journal.pone.0013770","article-title":"Study of the molecular recognition of aptamers selected through ovarian cancer cell-SELEX","volume":"5","author":"Van Simaeys","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.prp.2017.08.003_bib0010","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jnci\/djp450","article-title":"Designing early detection programs for ovarian cancer","volume":"102","author":"Hartge","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.prp.2017.08.003_bib0015","doi-asserted-by":"crossref","first-page":"740472","DOI":"10.1155\/2010\/740472","article-title":"Targeted therapy in ovarian cancer","volume":"2010","author":"Willmott","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.prp.2017.08.003_bib0020","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1093\/annonc\/mds315","article-title":"Optimal first-line treatment in ovarian cancer","volume":"23","author":"Raja","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.prp.2017.08.003_bib0025","first-page":"007822","article-title":"Cytoreductive surgery plus chemotherapy versus chemotherapy alone for recurrent epithelial ovarian cancer","volume":"6","author":"Galaal","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.prp.2017.08.003_bib0030","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2008.02.061","article-title":"Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors","volume":"265","author":"Chiacchiera","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2017.08.003_bib0035","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.4161\/cc.6.20.4774","article-title":"p38alpha: a suppressor of cell proliferation and tumorigenesis","volume":"6","author":"Hui","year":"2007","journal-title":"Cell Cycle"},{"key":"10.1016\/j.prp.2017.08.003_bib0040","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.canlet.2008.02.061","article-title":"Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38alpha in colorectal tumors","volume":"265","author":"Chiacchiera","year":"2008","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2017.08.003_bib0045","doi-asserted-by":"crossref","first-page":"537Y549","DOI":"10.1038\/nrc2694","article-title":"Signal integration by JNK and p38 MAPK pathways in cancer development","volume":"9","author":"Wagner","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.prp.2017.08.003_bib0050","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/IGC.0b013e3181c8ca12","article-title":"p38alpha is required for ovarian cancer cell metabolism and survival","volume":"20","author":"Matrone","year":"2010","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.prp.2017.08.003_bib0055","doi-asserted-by":"crossref","first-page":"20582","DOI":"10.1074\/jbc.M210992200","article-title":"The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair","volume":"278","author":"Hayakawa","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.prp.2017.08.003_bib0060","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.4161\/cc.6388","article-title":"ATF2: a transcription factor that elicits oncogenic or tumor suppressor activities","volume":"7","author":"Bhoumik","year":"2008","journal-title":"Cell Cycle"},{"key":"10.1016\/j.prp.2017.08.003_bib0065","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1128\/MCB.01579-06","article-title":"Reduced levels of ATF-2 predispose mice to mammary tumors","volume":"27","author":"Maekawa","year":"2007","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.prp.2017.08.003_bib0070","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1073\/pnas.0706057105","article-title":"Suppressor role of activating transcription factor 2 (ATF2) in skin cancer","volume":"105","author":"Bhoumik","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.prp.2017.08.003_bib0075","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1038\/nm.3679","article-title":"In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer","volume":"20","author":"Rudalska","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.prp.2017.08.003_bib0080","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1158\/1535-7163.111.3.2","article-title":"Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts","volume":"3","author":"Bani","year":"2004","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.prp.2017.08.003_bib0085","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1016\/j.humpath.2010.12.026","article-title":"Clinicopathologic significance of minichromosome maintenance protein 2 and Tat-interacting protein 30 expression in benign and malignant lesions of the gallbladder","volume":"42","author":"Liu","year":"2011","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2017.08.003_bib0090","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00001813-199807000-00007","article-title":"Human ovarian cancer xenografts in nude mice: chemotherapy trials with paclitaxel, cisplatin, vinorelbine and titanocene dichloride","volume":"9","author":"Villena-Heinsen","year":"1998","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.prp.2017.08.003_bib0095","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00124302","article-title":"The effectiveness of cis-platinum, cyclophosphamide and melphalan in treating disseminated tumor cells in mice","volume":"5","author":"Kanclerz","year":"1987","journal-title":"Clin. Exp. Metastasis"}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033817303394?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033817303394?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T16:16:59Z","timestamp":1659370619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033817303394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":19,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0344033817303394"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2017.08.003","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"p38MAPK family isoform p38\u03b1 and activating transcription factor 2 are associated with the malignant phenotypes and poor prognosis of patients with ovarian adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2017.08.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}